

September 2, 2026

National Stock Exchange of India Limited

Plot No. C/1, "G" Block, Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai 400 051

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Symbol: RPGLIFE

Security Code: 532983

Dear Sirs /Madam,

Sub: Outcome of Board Meeting

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, at its meeting held today, i.e., Wednesday, September 02, 2026, inter alia, considered and approved the execution of Business Transfer Agreement by its wholly owned subsidiary, RPG Active Pharma Limited with Raghava Life Sciences Private Limited for acquisition of Active Pharmaceutical Ingredients (APIs) and intermediates Businesses as a going concern, by way of slump sale.

The details required pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated January 30, 2026 is given in Annexure A to this letter.

The Board Meeting commenced at 7.00 pm and concluded at 8.10 pm.

Yours sincerely,

For RPG Life Sciences Ltd

Rajesh Shirambekar

Head – Legal & Company Secretary.

Encl: as above.

Annexure A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

Business Transfer Agreement between RPG Active Pharma Limited, a wholly owned subsidiary of the Company and Raghava Life Sciences Private Limited.

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	RPG Active Pharma Limited ("RPGAP"), the wholly owned subsidiary company of the Company, to acquire API and Intermediates Business Undertaking of Raghava Life Sciences Private Limited ("Raghava") through a Business Transfer Agreement on a going concern basis by way of slump sale. The transaction includes business with revenues of about Rs. 19 Crores in FY26 (unaudited) along with manufacturing facilities, R&D facility and portfolio of 29 API molecules of which 22 are commercialized and 7 are under development. No shares are being purchased in any entity and no entity is being acquired.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No. The Promoter / Promoter Group / Group Companies have no interest in the entity whose assets are being acquired.
3	Industry to which the entity being incorporated / acquired belongs	The Business being acquired pertains to Pharmaceutical Industry.
4	objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The acquisition is in line with the Company's strategy to expand its API business through its subsidiary Company.
5	Brief details of any governmental or regulatory approvals required for the acquisition	The transaction is subject to regulatory approvals, including approvals from local authorities, etc.
6	indicative time period for completion of the acquisition	It is expected that the transaction will be completed tentatively within 30 days or such period as may be mutually agreed, subject to satisfaction of closing conditions.

7	Consideration - whether cash consideration or share swap and details of the same	Cash Consideration
8	Cost of acquisition and/or the price at which the shares are acquired;	Since, this is a BTA transaction, business assets are being acquired and not shares of any entity. The transaction proposed does not involve acquisition of shares. The subject transaction is for consideration up to Rs. 135 crores (Rupees One Hundred and Thirty-Five crores) subject to customary adjustments and applicable taxes.
9	Percentage of shareholding / control by the listed entity and / or number of shares allotted.	
10	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Raghava Life Sciences Private Limited owns and operates the business of development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. Besides, Raghava was also into Contract Research Organization (CRO) / Contract Research and Manufacturing Services (CRAMS) business (which is not being acquired). Since this transaction pertains to purchase of Business, and not an acquisition of an entity, the disclosure of 3 years turnover, percentage of shareholding and number of shares, would not be applicable.